CU6 12.1% $7.67 clarity pharmaceuticals ltd

Ann: Theranostic prostate cancer trial advances to cohort 3, page-2

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 7,168 Posts.
    lightbulb Created with Sketch. 1834
    This reads as good news to me. As a newbie I have a couple of questions. Appreciate if someone can help me.

    1. While the Ann is for prostrate cancer, the images shown are for lesions in the vertebra and shoulder? What’s the connection?

    2. The next phase will be dose expansion followed by phase 2?

    Thanks.
 
watchlist Created with Sketch. Add CU6 (ASX) to my watchlist
(20min delay)
Last
$7.67
Change
-1.060(12.1%)
Mkt cap ! $2.451B
Open High Low Value Volume
$8.62 $8.68 $7.67 $13.44M 1.664M

Buyers (Bids)

No. Vol. Price($)
2 21192 $7.67
 

Sellers (Offers)

Price($) Vol. No.
$7.72 59 1
View Market Depth
Last trade - 16.10pm 04/10/2024 (20 minute delay) ?
CU6 (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.